Dengue Disease Vaccine
 Rationale   Dengue is a viral infection transmitted to humans through the bite of an infected   Aedes   mosquito. It is not transmitted directly from person to person. Nevertheless, the virus which replicates in an infected individual can be transmitted to other humans through mosquito bites. Usually, the first symptom appears 4-5 days (maximum of 12 days) after the mosquito bite.    Dengue disease results in a wide range of symptoms including fever, headache, pain behind the eyes, muscle and joint pain, nausea, vomiting, swollen glands or skin rash. Symptoms usually last for 2-7 days. The disease can also be asymptomatic.    Occasionally, dengue can be severe and potentially lead to hospitalization and in rare cases to death. Severe dengue is characterized by high fever and any of the following symptoms: severe abdominal pain, persistent vomiting, rapid breathing, severe bleeding, bleeding in the stomach, bleeding gums, fatigue, restlessness, coma, seizure, and organ failure.    Due to possible death resulting from a dengue disease, it is very important that you avail of this vaccination.       Generic and brand names   The generic name is dengue tetravalent vaccine (live, attenuated). The brand name is: Dengvaxia.    Composition of the vaccine   Dengvaxia contains dengue virus serotypes 1, 2, 3, and 4 that have been weakened.
            